在线血液透析滤过在当代肾脏护理中的作用
本文综述了在线血液透析滤过(OL-HDF)的技术优势、疗效证据及临床实施要求。疗效试验显示HDF在溶质清除、血流动力学耐受性和生存率方面优于高通量血液透析,需达到每 session 23 L(按体表面积调整)的对流体积。2024年美国FDA批准OL-HDF,为肾衰竭患者管理提供新选择。
要点
- HDF在溶质清除、血流动力学耐受性和生存率方面优于高通量血液透析。
- 每 session 对流体积目标为23 L(按体表面积调整),需血流量≥350 ml/min。
- 在线制备置换液(OL-HDF)降低成本并简化操作,2024年获FDA批准。
核心结论
- 在线血液透析滤过(OL-HDF)在溶质清除、血流动力学耐受性和生存率方面优于高通量血液透析。
- 2024年美国FDA批准OL-HDF,为肾衰竭患者管理提供新选择。
研究设计与样本
- 本文为综述,总结了HDF疗效试验证据及技术实施要求。
主要发现
- 疗效试验显示HDF在溶质清除、血流动力学耐受性和生存率方面优于高通量血液透析。
- HDF在欧洲和亚洲获得应用,需达到每 session 23 L(按体表面积调整)的对流体积以最大化获益。
- 在线制备置换液(OL-HDF)降低成本并简化操作,使技术安全便捷。
关键数值与推荐
- 对流体积目标:每 session 23 L,按体表面积调整(23 L乘以个体BSA与1.73 m²的比值)。
- 血流量需≥350 ml/min,需使用14-15 Gauge针或≥14 French导管以避免过度血液浓缩和回路压力问题。
临床怎么用
- 临床实施OL-HDF需确保血流量≥350 ml/min并达到按BSA调整的23 L对流体积。
- 在线制备置换液可降低成本和复杂性,提高操作便捷性。
局限性
- 美国早期因法规和安全担忧未批准OL-HDF,2024年才获FDA批准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Replacement of kidney function by dialysis maintains the lives of millions of patients. Clinical results however are still unsatisfactory with mortality rates and complications well above the matched control population. This has led to a continuous quest for more effective dialysis techniques and new biomaterials. In the 1980s, the production of synthetic membranes with higher water permeability ( i.e ., high flux) leveraged the development of techniques, such as hemodiafiltration (HDF), with improved solute removal, thanks to combination of diffusion and convection. Efficacy trials have demonstrated the superiority of HDF over high-flux hemodialysis for solute removal, hemodynamic tolerance, and survival. Consequently, the technique gained traction in Europe and Asia. In these trials, a minimum target convection volume ( i.e ., fluid replaced) of 23 L per session adjusted to body surface area (BSA, i.e ., 23 L multiplied by ratio of individual BSA normalized by 1.73 m 2 ) was required to maximize the benefit of the therapy. In general, the replacement fluid is delivered in the postfilter site, and to attain this target of 23 L adjusted to BSA, blood flows must be ≥350 ml/min, requiring 14-15 Gauge needles or ≥14 French catheters to avoid excessive hemoconcentration and circuit pressure issues. In its early days, the replacement solution was provided with sterile bags (offline), making the therapy costly and cumbersome. Online (OL), i.e ., real-time preparation of ultrapure fluid for replacement, has become the key to reduce cost and complexity, while making the technique (OL-HDF) safe and convenient. In the United States, however, existing regulations and concerns about safety prevented approval for clinical use. In 2024, OL-HDF has received approval by the US Food and Drug Administration in the United States, and this opens new options and perspectives in the management of people living with kidney failure.
引用
- Ronco C, Maduell F, Kalantar-Zadeh K, et al. The Role of Online Hemodiafiltration in Contemporary Kidney Care. Clin J Am Soc Nephrol. 2025. PMID: 41051878. doi:10.2215/CJN.0000000920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。